Indivior Pharmaceuticals, Inc. INDV Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's business segments — net income?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — net income of $89M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's business segments — net income changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's business segments — net income increased by 89.4% year-over-year, from $47M to $89M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's business segments — net income?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's business segments — net income has grown at a 68.1% compound annual growth rate (CAGR), from -$44M to $209M.
- What does business segments — net income mean?
- This represents the final profit or loss attributable to the reportable segment after all operating expenses, taxes, and non-operating items have been deducted. It is the definitive measure of the segment's overall financial success and value creation.